Drug Profile

Salvinorin A - ATAI Life Sciences/IntelGenx

Alternative Names: INT0054/2020; RLS-01; Salvinorin-A

Latest Information Update: 12 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Revixia Life Sciences
Developer IntelGenx Corp.; Revixia Life Sciences
Class Behavioural disorder therapies; Mood stabilisers; Neuropsychotherapeutics; Small molecules; Vascular disorder therapies
Mechanism of Action Opioid kappa receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Depressive disorders; Unspecified

Most Recent Events

21 Mar 2024 Discontinued - Preclinical for Depressive disorders in Germany (unspecified route)
21 Mar 2024 Discontinued - Preclinical for Unspecified in Germany (unspecified route)
04 May 2023 IntelGenx SEC filing, December 2022 : KDM updated, HE added

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com